CoNCERT is creating new medicines through a
novel scientific approach utilizing the naturally-occurring element
deuterium. It applies its innovative platform to modify specific properties
of validated drug molecules, yielding a rich pipeline of new chemical
entities. CoNCERT leverages decades of pharmaceutical experience to create
drug candidates with potential for best-in-class efficacy and safety, while
greatly reducing R&D risk, time and expense. The Company has over 100 patent
applications for new drug candidates addressing a broad range of therapeutic
areas, including hot flashes, fibrotic diseases, pain and infectious
disease. Concert currently has technology licensing deals with Celgene, Jazz
Pharmaceuticals and Avanir Pharmaceuticals. The company owns a number of
additional preclinical and clinical assets which it has not yet licensed.
The most advanced candidate is currently be evaluated in a Phase II trial to
treat chronic kidney disease.
Co-investors include Adage Capital
Management L.P., SR One Ltd., Westfield Capital Management, Three Arch
Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund,
LP, Flagship Ventures, Greylock Partners, New Leaf Venture Partners, and QVT
Fund LP. Paul Howard is a Board observer.
DiscoveRx develops a portfolio of high
performance cell and biochemical reagents for use in a broad range of drug
discovery and toxicology assays. These assays include drug lead
identification in high throughput screening as well as drug target
identification and validation in proteomic ,genomic and primary human cell
Co-investors in the company include Skyline Ventures, Morgan
Stanley Ventures and Alta Partners. Paul Howard is a Board observer.
PatientKeeper develops software for
hand-held devices (PDAs) for physicians and allied health personnel.
Applications include computerized physician order entry (CPOE), charge
capture, clinical results, prescriptions and dictation. The company also
provides a sophisticated back-end database and synchronizing capability.
PatientKeeper’s customers include major teaching hospitals and community
Co-investors include NEA, Frazier and Co. and J.H.
Whitney and Co. Larry Miller is a member of the Board and Paul Howard is a
Relypsa, Inc. is a biopharmaceutical
company focused on the discovery and development of new non-absorbed
polymeric drugs which exert their therapeutic effects within the
gastro-intestinal tract. Relypsa’s lead product is a potassium binder that
is being developed to manage hyperkalemia, a potential life-threatening side
effect which can develop from drugs used to manage chronic kidney disease
(CKD) and congestive heart failure (CHF). The company recently completed the
enrollment of two Phase III trials under an FDA approved SPA (special
protocol assessment) and expects to file an NDA by the first quarter of
Co-investors include, 5AM Ventures, New Leaf Delphi and
Orbimed. Paul Howard is a Board observer.
STARTech is a Dallas-based "accelerator"
providing early stage companies with a broad range of financial, legal and
administrative assistance, including the services of experienced "mentors"
who can provide direct tactical and strategic advice. The company focuses on
information technology approaches to health care and other sectors.
Co-investors include Sevin Rosen, InterWest Partners, Rho Management and
Supplemental provides staffing services to
hospitals and other health care facilities, including traveling and local
staffing of nurses, physicians and ancillary hospital personnel, such as
radiology technicians, physical therapists, and occupational therapists.
Supplemental is one of the top ten nurse and therapist staffing companies in
Co-investors include GE Capital and Dauphin Capital
Partners. Paul Howard is a member of the Board.
Tetraphase Pharmaceuticals was founded by
Mediphase. The company develops antibiotics in the tetracycline class, based
on synthetic technology developed by Prof. Andrew Myers and licensed from
Harvard University. The company which recently went public (TTPH: NASDAQ)
expects to begin Phase III trials in the 2H 2013 and report data in 1Q 2015.
Co-investors include Fidelity Biosciences, Skyline Ventures, Flagship
Ventures, Excel Ventures and CMEA Ventures.
Wellpartner develops both traditional
pharmacy benefits management products as well as 340B products and services
for hospitals and commercial healthcare insurers. An important
differentiator in the company’s product offering is its 340B program which
is a combination of services and software to provide low cost drugs to
patients in need. The government established the 340B program in the 1990s
in conjunction with drug manufacturers in order to provide drugs to the
poorest patients. In the past, this program has been underutilized due to
the complexity of regulatory rules required to administer the plan.
Wellpartner’s product simplifies and automates this process.
Co-investors include 3i Technology Partners, Integra Ventures, and Buerk
Dale Victor. Paul Howard is a Board observer.
HMS develops healthcare data sets which support customer targeting, resource allocation and new ways to track and measure ROI. HMS solutions span licensing of databases, building custom data sets, and providing data matching, integration, and integrity validation services.
HMS was acquired by a group of investors in October 2007.
The pioneer in measuring impact of promotion on physician prescribing behavior, ImpactRx was founded by Mediphase, and acquired by Symphony Technology group in 2011.
Optio Research, Inc.
Optio Research was founded by Mediphase.
Acquired by Health Market Science, 2005.
PharMetrics was founded by Mediphase.
Acquired by IMS Health in July, 2005.
Rosetta Inpharmatics, Inc.
Acquired by Merck, May, 2001
Roxro Pharma, Inc.
Menlo Park, CA
In May, 2010, Roxro Pharma’s product, intranasal analgesic SPRIX™, was approved by the FDA for treatment of acute pain.
Roxro was acquired by Luitpold Pharmaceuticals in December, 2010.
Serenex was founded by Mediphase. Serenex develops therapeutics to both treat the primary causes of cancer as well to treat the side effects associated with the use of chemotherapeutic agents. The company was acquired by Pfizer in April 2008.
Targanta Therapeutics, Inc.
Targanta is developing antibiotics for the treatment of serious infections. The company was acquired by The Medicines Company in February 2009.
Triad Therapeutics, Inc.
San Diego, CA
Triad develops targeted drug candidates through NMR spectroscopy guided
techniques. In December 2004, the company completed an asset sale
transaction with Novartis to develop and market Triad’s drug candidates.
Xenoport (NASDAQ: XNPT) develops technology to improve the oral absorption and pharmacokinetic properties of drugs, using active transport systems found in the human gastrointestinal tract. Xenoport has reported successful Phase II trials with a pro-drug of gabapentin (Neurontin) for use in treating restless legs syndrome, and will begin Phase III trials in late 2006. A second pro-drug, Baclofen, recently completed Phase II clinical trials for the treatment GERD.
Zyomyx has developed an extensive
collection of proprietary technologies for the production and analysis of
protein arrays. The company is outlicensing these technologies through a
number of commercial contract R&D arrangements.